SEATTLE, Sept. 18, 2024 (GLOBE NEWSWIRE) — Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal second quarter 2025 financial results on Tuesday, October 8, 2024 before market open. In conjunction, the company will host a conference call to review results at 8:00 a.m. E.T. on the same day.
Conference Call Details
To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here (https://register.vevent.com/register/BI0b6b999c6e7b47fdb26d7e8a774df09f). Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN.
To Listen via Internet: The conference call can be accessed via a live audio webcast that will be available online at http://ir.accolade.com .
Replay: A replay of the call will be available for one year via webcast for on-demand listening shortly after the completion of the call, at http://ir.accolade.com.
About Accolade, Inc.
Accolade (Nasdaq: ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare experiences so they can live their healthiest lives. Accolade’s employer, health plan, and consumer solutions combine virtual primary care and mental health, expert medical opinion, and best-in-class care navigation. These offerings are built on a platform that is engineered to care through predictive engagement of population health needs, proactive care that improves outcomes and cost savings, and by addressing barriers to access and continuity of care. Accolade consistently receives consumer satisfaction ratings of over 90%. For more information, visit accolade.com. Follow us on LinkedIn, Twitter, Instagram and Facebook.
Investor Contact:
Todd Friedman, Investor Relations, IR@accolade.com
Media Contact:
Media Inquiries, Media@accolade.com
Source: Accolade
This press release was published by a CLEAR® Verified individual.


Đề xuất
Nebu Ease Portable Nebulizer Claims Evaluated: 2026 Consumer Research Report on Mesh Nebulizer Technology, Respiratory Comfort Features, and What Buyers Should Verify
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
TrimRx Telehealth Weight Loss Platform Examined in 2026 Consumer Research Report on GLP-1 Medication Access, Pricing Transparency and Safety Considerations
Sherry Cummings, CEO of Gryphon Healthcare, Named One of the Top 50 Women to KNOW in Texas
Direct Meds GLP-1 Program Report 2026: Compounded Semaglutide and Tirzepatide Pricing, Telehealth Access, and Consumer Verification Factors
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference